AstraZeneca: AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer

AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for the prostate cancer indication.Korea Biomedical Review has learned that AstraZeneca Korea submitted a reimbursement application for Lynparza to the Health Insurance Review and Assess